title: Hepatobiliary cancers, version 2.2014.
abstract: Hepatobiliary cancers include a spectrum of invasive carcinomas arising in the liver (hepatocellular carcinoma), gall bladder, and bile ducts (cholangiocarcinomas). Gallbladder cancer and cholangiocarcinomas are collectively known as biliary tract cancers. Gallbladder cancer is the most common and aggressive type of all the biliary tract cancers. Cholangiocarcinomas are diagnosed throughout the biliary tree and are typically classified as either intrahepatic or extrahepatic cholangiocarcinoma. Extrahepatic cholangiocarcinomas are more common than intrahepatic cholangiocarcinomas. This manuscript focuses on the clinical management of patients with gallbladder cancer and cholangiocarcinomas (intrahepatic and extrahepatic).
authors.forename: Al B
authors.initials: AB
authors.lastname: Benson
authors.forename: Michael I
authors.initials: MI
authors.lastname: D'Angelica
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Abrams
authors.forename: Chandrakanth
authors.initials: C
authors.lastname: Are
authors.forename: P Mark
authors.initials: PM
authors.lastname: Bloomston
authors.forename: Daniel T
authors.initials: DT
authors.lastname: Chang
authors.forename: Bryan M
authors.initials: BM
authors.lastname: Clary
authors.forename: Anne M
authors.initials: AM
authors.lastname: Covey
authors.forename: William D
authors.initials: WD
authors.lastname: Ensminger
authors.forename: Renuka
authors.initials: R
authors.lastname: Iyer
authors.forename: R Kate
authors.initials: RK
authors.lastname: Kelley
authors.forename: David
authors.initials: D
authors.lastname: Linehan
authors.forename: Mokenge P
authors.initials: MP
authors.lastname: Malafa
authors.forename: Steven G
authors.initials: SG
authors.lastname: Meranze
authors.forename: James O
authors.initials: JO
authors.lastname: Park
authors.forename: Timothy
authors.initials: T
authors.lastname: Pawlik
authors.forename: James A
authors.initials: JA
authors.lastname: Posey
authors.forename: Courtney
authors.initials: C
authors.lastname: Scaife
authors.forename: Tracey
authors.initials: T
authors.lastname: Schefter
authors.forename: Elin R
authors.initials: ER
authors.lastname: Sigurdson
authors.forename: G Gary
authors.initials: GG
authors.lastname: Tian
authors.forename: Jean-Nicolas
authors.initials: JN
authors.lastname: Vauthey
authors.forename: Alan P
authors.initials: AP
authors.lastname: Venook
authors.forename: Yun
authors.initials: Y
authors.lastname: Yen
authors.forename: Andrew X
authors.initials: AX
authors.lastname: Zhu
authors.forename: Karin G
authors.initials: KG
authors.lastname: Hoffmann
authors.forename: Nicole R
authors.initials: NR
authors.lastname: McMillian
authors.forename: Hema
authors.initials: H
authors.lastname: Sundar
mesh_terms: D001650:Bile Duct Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D001653:Bile Ducts, Intrahepatic / Q000473:pathology; D006528:Carcinoma, Hepatocellular / Q000473:pathology / Q000628:therapy*; D018281:Cholangiocarcinoma / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D005706:Gallbladder Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy*; D017408:Guidelines as Topic; D006801:Humans; D008113:Liver Neoplasms / Q000473:pathology / Q000628:therapy; D016032:Randomized Controlled Trials as Topic